TPOP146

Research use only, not for human use.

A potent and selective CBP/p300 bromodomain inhibitor with Kd of 134 nM for CBP bromodomain.

A potent and selective CBP/p300 bromodomain inhibitor with Kd of 134 nM for CBP bromodomain, displays excellent selectivity over other bromodomains (>30-fold over BRD4 (1)); targets the CBP bromodomain in the nucleus and is capable of competing with acetyl-lysine mediated interactions of the CBP bromodomain in cellular environments.

Exposure to 1 μM TPOP146 results in a significant decrease of recovery half-life that is comparable to the construct that contained the bromodomain inactivating mutation N1168F, demonstrating that TPOP146 targets the CBP bromodomain in the nucleus and is capable of competing with acetyl-lysine mediated interactions of the CBP bromodomain in cellular environments. They are for reference only.

——

TPOP-146 | TPOP 146

Chromatin/Epigenetic

Bromodomain

Bromodomain

——

——

2018300-62-2

481.5839

C27H35N3O5

>98% (HPLC)

DMSO

COC1=CC(C2=CC(C(N[C@H]3CCCN(C)C3)=O)=C(OCCN(C(CC)=O)C4)C4=C2)=CC(OC)=C1

1,4-Benzoxazepine-9-carboxamide, 7-(3,5-dimethoxyphenyl)-2,3,4,5-tetrahydro-N-[(3S)-1-methyl-3-piperidinyl]-4-(1-oxopropyl)-

(-20℃)

With Ice Pack

≥ 2 years